Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Background: We performed an individual patient data meta-analysis to examine the impact of first-generation epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor (TKI) therapy on overall survival (OS) in advanced non-small cell lung cancer (NSCLC). Methods: Data from trials comparing E...

Saved in:

書目詳細資料
Main Authors:	Chee Khoon Lee, Lucy Davies, Yi Long Wu, Tetsuya Mitsudomi, Akira Inoue, Rafael Rosell, Caicun Zhou, Kazuhiko Nakagawa, Sumitra Thongprasert, Masahiro Fukuoka, Sally Lord, Ian Marschner, Yu Kang Tu, Richard J. Gralla, Val Gebski, Tony Mok, James Chih Hsin Yang
格式:	雜誌
出版:	2018
主題:	Agricultural and Biological Sciences
在線閱讀:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85027265241&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/46393
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!
機構:	Chiang Mai University

相似書籍

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Chee Khoon Lee, et al.
出版: (2018)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
由: Lee C., et al.
出版: (2017)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
由: Wong, A.S., et al.
出版: (2014)

Contribution of EGFR and ErbB-3 heterodimerization to the EGFR mutation-induced gefitinib- and erlotinib-resistance in non-small-cell lung carcinoma treatments
由: Wang D.D., et al.
出版: (2019)

EGFR Mutant Structural Database: Computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib
由: Ma, L, et al.
出版: (2020)

EFFICACY OF GEFITINIB AND ERLOTINIB IN NON-SMALL-CELL LUNG CARCINOMA
由: Afrita Amalia Laitupa, -, et al.
出版: (2019)

Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer
由: Wong, A.S., et al.
出版: (2014)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
由: Natthaporn Sueangoen, et al.
出版: (2020)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Masahiro Fukuoka, et al.
出版: (2018)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
由: Tony Mok, et al.
出版: (2018)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
由: Tony Mok, et al.
出版: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
由: Chee Khoon Lee, et al.
出版: (2018)

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis
由: Chee Khoon Lee, et al.
出版: (2018)

Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
由: Yeo, W.-L., et al.
出版: (2011)

EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter
由: Voon, P.J., et al.
出版: (2014)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Fukuoka M., et al.
出版: (2017)

Editorial: Update on Anti-EGFR therapy
由: Daniel Chua, et al.
出版: (2018)

Editorial: Update on Anti-EGFR therapy
由: Daniel Chua, et al.
出版: (2018)

PERBANDINGAN RESPONS TERAPI GEFITINIB PADA PASIEN KPKBSK DENGAN EGFR MUTASI EXON 19 DAN EXON 21
由: Titin Sholihah Agustina, NIM011180901
出版: (2017)

PERBANDINGAN EFIKASI GEFITINIB DAN ERLOTINIB PADA PASIEN KANKER PARU JENIS KARSINOMA BUKAN SEL KECIL DI POLI ONKOLOGI SATU ATAP RS DR SOETOMO SURABAYA
由: Afrita Amalia Laitupa
出版: (2019)

Erlotinib in previously treated non-small-cell lung cancer
由: Frances A. Shepherd, et al.
出版: (2018)

EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth
由: Assiddiq, B.F., et al.
出版: (2014)

Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A phase III trial
由: Giorgio V. Scagliotti, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Wu Y., et al.
出版: (2017)

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
由: Reungwetwattana T.
出版: (2023)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Lung cancer working group report
由: Nagahiro Saijo, et al.
出版: (2018)

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
由: Cho B.C.
出版: (2023)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
由: Suresh S. Ramalingam, et al.
出版: (2020)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
由: Suresh S. Ramalingam, et al.
出版: (2020)

Efficacy of dose modification of gefitinib after hepatotoxicity in late-line treatment of EGFR mutated advanced non-small cell lung cancer: A case report
由: Chaichana Chantharakhit
出版: (2019)

Sunitinib Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer: A Phase III Trial
由: Scagliotti G.V., et al.
出版: (2014)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
由: Sumitra Thongprasert, et al.
出版: (2018)

SYNTHESIS OF QUINAZOLINE DERIVATIVES AS GEFITINIB INTERMEDIATES
由: Auliya Hafizah, Raysa

Serum concentrations of erlotinib at a dose of 25 mg daily
由: Costa, D.B., et al.
出版: (2014)